STEPHANIE STEVENSON: Open Payments
NPI 1659456184 · DETROIT, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,798 in 78 payments from 10 companies in 2025. Trend: 2023 $838 · 2024 $867 · 2025 $1,798
Food & beverage: $1,698Education: $100
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 15 | $434 |
| Neurocrine BioSciences, Inc. | 17 | $414 |
| Janssen Pharmaceuticals, Inc | 11 | $272 |
| Otsuka America Pharmaceutical, Inc. | 16 | $181 |
| Teva Pharmaceuticals USA, Inc. | 6 | $170 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $116 |
| Luye Pharma (USA) Ltd. | 2 | $89 |
| Alkermes, Inc. | 3 | $88 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $17 |
Products named: COBENFY, INGREZZA, INVEGA SUSTENNA, ABILIFY MAINTENA, CAPLYTA, ERZOFRI EXTENDED-RELEASE, REXULTI, ARISTADA.
Industry payments across MI — which companies pay providers there.
